Related Experiment Video
Updated: Sep 6, 2025
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis
Laura Barbolini1, Arnaud Riat2, Christian Van Delden3
1Internal Medicine Division, Dept of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Abstract:
Relying on a biomarker to diagnose or follow up the treatment of a Candida albicans meningitis would have an impact on patient management. The biomarker 1,3, β-D-glucan (BDG), developed for serum testing, shows inconsistent values when applied on cerebrospinal fluid (CSF), and its use with the current protocol on CSF samples warrants caution.
More Related Videos
08:31Candida albicans Biofilm Development on Medically-relevant Foreign Bodies in a Mouse Subcutaneous Model Followed by Bioluminescence Imaging
Published on: January 27, 2015
06:50A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022